Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
It is thought that treating multiple sclerosis with Novantrone for a short period of time prior to treatment with Copaxone may enhance the onset effect of Copaxone.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Copaxone 20 mg | Active Comparator | Copaxone 20 mg |
|
| Copaxone 20mg with Novantrone induction | Active Comparator | Copaxone 20mg with Novantrone induction |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| glatiramer acetate 20 mg | Drug | glatiramer acetate 20 mg |
|
| Measure | Description | Time Frame |
|---|---|---|
| Determine if short-term immunosuppression with mitoxantrone (Novantrone®) followed by chronic treatment with Glatiramer Acetate (GA) in comparison to treatment with GA for the same period of time but without immunosuppression is well-tolerated and safe | 15 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patients ever treated with Glatiramer Acetate or Mitoxantrone.
Patients treated with interferons or IV immunoglobulins (IV Ig) in the previous 4 weeks prior to screening visits.
Patients treated with methotrexate or azathioprine in the previous 6 months prior to screening visits.
Patients ever treated with cyclophosphamide or Total Lymphoid Irradiation (TLI), or cladribine for injection or anthracenediones or anthracyclines, or prior mediastinal radiotherapy.
Patients treated with intravenous or oral steroids within 28 days prior to initial MRI.
Female patients must be non-pregnant, non-lactating, have a negative screening pregnancy test, and must use contraceptive methods deemed reliable by the investigator.
Male patients and their partners must use contraceptive methods deemed reliable by the investigator
LVEF < 50%
Patients using catheters or Foley catheters
Patients who have any other known significant systemic medical disease which may confound the evaluation of the study results such as: ALS, cervical spondylitic myelopathy, syphilis, arteritis, cerebellar syndrome (i.e., due to heredodegeneration), B12/folate deficiency, lyme disease, HTLV 1-myelopathy
Patients with immune deficiency or other medical condition that would preclude treatment with Mitoxantrone or Glatiramer Acetate
Abnormal screening blood tests exceeding any of the limits defined below:
Alanine transaminase (ALT) - twice the upper limit of normal Aspartate transaminase (AST) - twice the upper limit of normal Total white blood cell count < 2.3 x 103/uL Baseline neutrophil counts of < 1.5 x103/uL Platelet count < 80 x 103/uL Creatinine >1.5 mg/dL Prothrombin time greater than 150% upper limit of normal
Patients with any medical or psychiatric conditions that would make the patient unsuitable for this research, as determined by the investigator.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Siyu Liu, MD | Teva Neuroscience, Inc. | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| glatiramer acetate 20 mg, with mitoxantrone | Drug | glatiramer acetate 20 mg, with mitoxantrone |
|
|
| ID | Term |
|---|---|
| D020529 | Multiple Sclerosis, Relapsing-Remitting |
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068717 | Glatiramer Acetate |
| D008942 | Mitoxantrone |
| ID | Term |
|---|---|
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D000880 | Anthraquinones |
| D000095322 | Anthrones |
| D000873 | Anthracenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D011809 | Quinones |
| D011083 | Polycyclic Compounds |
Not provided
Not provided